There is no evidence of an association between research and development costs and prices of prescription drugs

From JAMA: “[inlinetweet prefix=”” tweeter=”” suffix=””]Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices[/inlinetweet]; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear”. And I guess most pharma executives believe the market can bear a lot more. Continue reading

Pharma: Tax dodgers and price gougers?

KEY POINTS:

-[inlinetweet prefix=”” tweeter=”” suffix=””]Between 2011 and 2015, the Pharma Big 10 jacked up the prices charged to consumers and Medicare and Medicaid for 31 of their most widely-prescribed drugs by at least 40% and as much as 71%[/inlinetweet].

    • -[inlinetweet prefix=”” tweeter=”” suffix=””]Worldwide corporate profits of the Pharma Big 10 jumped by 39% over 2011-2015, from $58.8 billion to $81.5 billion (and to $83.4 billion, or by 42%, between 2011 and 2016).[/inlinetweet]
    Worldwide sales, which neared $300 billion in 2015, were up only 5% over that timeframe, indicating drug companies were squeezing more pro t from every sale.

-[inlinetweet prefix=”” tweeter=”” suffix=””]The Pharma Big 10 had $506 billion in untaxed profits stashed offshore in 2016. [/inlinetweet]

Continue reading

Pharma finally admits “digital is important”

KEY TAKEAWAY: GSK and Novartis have gone to the outside to hire senior digital marketing people with CPG experience.  While these moves are long overdue is it enough or is pharma waiting at the airport for their ship to come in? Continue reading

Amgen fights for its new cholesterol drug

KEY TAKEAWAY: A study in JAMA found  “a Markov cohort state-transition model determined that adding evolocumab at current list price to patients receiving standard background therapy was estimated to cost $268 637 per quality-adjusted life-year gained. Sensitivity and scenario analyses demonstrated incremental cost-effectiveness ratios ranging from $100 193 to $488 642 per quality-adjusted life-year.” Will this be enough to sway insurers to say “ok”? Continue reading

Senate Republicans stick it to Medicaid patients while pharma remains silent

It would be a big mistake to call the legislation Senate Republicans released on Thursday a health care bill. It is, plain and simple, a plan to cut taxes for the wealthy by destroying critical federal programs that help provide health care to tens of millions of people. Even with this charade pharma seems happy because “they got what they want” from this President. Continue reading